• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    4/3/23 1:31:20 PM ET
    $ANVS
    $ASND
    $BDRX
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANVS alert in real time by email

    Gainers

    • Cano Health (NYSE:CANO) shares increased by 46.1% to $1.33 during Monday's regular session. Trading volume for this security as of 13:30 EST is 27.8 million, which is 333.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $351.3 million.
    • Pulse Biosciences (NASDAQ:PLSE) stock rose 25.0% to $4.2. Trading volume for this security as of 13:30 EST is 369.8K, which is 666.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $156.3 million. As per the press release, Q4 earnings came out 2 days ago.
    • Passage Bio (NASDAQ:PASG) stock increased by 23.73% to $1.19. Trading volume for this security as of 13:30 EST is 605.8K, which is 385.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $64.7 million.
    • Celularity (NASDAQ:CELU) stock increased by 21.06% to $0.75. Celularity's stock is trading at a volume of 996.5K shares as of 13:30 EST. This is 169.5% of its average full-day volume over the last 100 days. The company's market cap stands at $115.3 million.
    • Heska (NASDAQ:HSKA) shares moved upwards by 20.43% to $117.57. Trading volume for this security as of 13:30 EST is 1.5 million, which is 1240.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.2 billion.
    • SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 20.27% to $1.72. Trading volume for SELLAS Life Sciences Gr's stock is 482.2K as of 13:30 EST. This is 109.5% of its average full-day volume over the last 100 days. The company's market cap stands at $48.6 million.

    Losers

    • OncoSec Medical (NASDAQ:ONCS) stock decreased by 50.8% to $1.27 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 2.4 million shares, making up 113.3% of its average full-day volume over the last 100 days. The company's market cap stands at $3.7 million.
    • Palisade Bio (NASDAQ:PALI) shares declined by 33.24% to $2.35. Trading volume for this security as of 13:30 EST is 4.5 million, which is 138.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.5 million.
    • Ascendis Pharma (NASDAQ:ASND) shares fell 30.59% to $74.43. As of 13:30 EST, this security is trading at a volume of 5.6 million shares, making up 2210.0% of its average full-day volume over the last 100 days. The company's market cap stands at $4.2 billion.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares fell 24.44% to $0.29. Trading volume for this security as of 13:30 EST is 5.5 million, which is 45.9% of its average full-day volume over the last 100 days.
    • Annovis Bio (NYSE:ANVS) stock fell 22.78% to $11.9. Trading volume for Annovis Bio's stock is 380.7K as of 13:30 EST. This is 551.9% of its average full-day volume over the last 100 days. The company's market cap stands at $97.1 million.
    • Bionomics (NASDAQ:BNOX) shares declined by 20.0% to $2.08. The current volume of 86.6K shares is 65.3% of Bionomics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $16.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANVS
    $ASND
    $BDRX
    $BNOX

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Ascendis Pharma A/S
    $ASND
    1/28/2026$342.00Overweight
    Barclays
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Ascendis Pharma A/S
    $ASND
    11/18/2025$255.00Peer Perform
    Wolfe Research
    Ascendis Pharma A/S
    $ASND
    10/17/2025$271.00Strong Buy
    Raymond James
    More analyst ratings

    $ANVS
    $ASND
    $BDRX
    $BNOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Hoffman Michael B bought $193,794 worth of shares (45,000 units at $4.31), increasing direct ownership by 2% to 2,574,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    12/8/25 8:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $ASND
    $BDRX
    $BNOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Danahy Kevin Patrick exercised 5,000 shares at a strike of $1.53 and sold $118,200 worth of shares (5,000 units at $23.64) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/23/26 8:55:39 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Danahy Kevin Patrick exercised 60,000 shares at a strike of $1.53 and sold $1,410,600 worth of shares (60,000 units at $23.51) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/17/26 8:47:42 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANVS
    $ASND
    $BDRX
    $BNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets resumed coverage on Passage BIO with a new price target

    Chardan Capital Markets resumed coverage of Passage BIO with a rating of Buy and set a new price target of $21.00

    2/10/26 6:56:48 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ANVS
    $ASND
    $BDRX
    $BNOX
    SEC Filings

    View All

    Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    3/12/26 9:20:34 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    3/11/26 4:06:38 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    3/11/26 4:06:12 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $ASND
    $BDRX
    $BNOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its

    3/12/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

    - Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -- Topline Data Expected in Q4 2026 – NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the first patient has been enrolled in its randomized Phase 2 trial evaluating SLS009 (tambiciclib), a highly selective CDK9 inhibitor in newly diagnosed, first-line acute myeloid leuk

    3/12/26 8:35:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

    Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics. FLORHAM PARK, N.J., March 12, 2026

    3/12/26 8:30:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ANVS
    $ASND
    $BDRX
    $BNOX
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANVS
    $ASND
    $BDRX
    $BNOX
    Financials

    Live finance-specific insights

    View All

    FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

    The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher granted in connection with approvalAscendis to host investor conference call Monday, March 2, at 8:00 am ET COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growt

    2/27/26 5:57:16 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv

    2/19/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

    Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,"

    2/11/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $ASND
    $BDRX
    $BNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 5:46:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care